Due to Britain leaving the European Union, the European Medicines Agency (EMA) will have to relocate from London, and may become inaccessible to staff as a result. Reuters reports "cancer drugs and therapies for rare diseases could be particularly affected by an exodus of key scientific and administrative staff during the move." Depending on the new location, between 19 and 94 percent of staff may leave. Reuters also says that the drug regulator has no back-up plan and would have to shut down if its too inaccessible. This would delay drug approvals and could require Europe to import drugs. What are your thoughts?